Table 2.
Susceptibility profile of Gram-positive bacilli and Gram-positive cocci isolated from human skin allografts with and without antimicrobial treatment
| Gram-Positive Bacilli | Gram-Positive Cocci | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Antimicrobial resistance profile | Number of isolates (n = 195) | Isolates | Treatment | Antimicrobial resistance profile | Number of isolates (n = 124) | Isolates | Treatment | ||||
| WT | 1ST | 1ST/2ND | WT | 1ST | 1ST/2ND | ||||||
| PEN CFO |
27 1 |
B. cereus
B. subtilis B. licheniformis Bacillus sp. B. vallismortis |
2 1 9 3 1 |
— — — — |
12 — — — — |
PEN CFO AZM |
20 1 13 |
S. aureus
S. lugdunensis CNS S. haemolyticus CNS |
19 1 — 12 — |
— — 1 — 1 |
— — — — — |
| PEN–CFO CFO–EST PEN–AZM |
59 4 1 |
B. cereus
Paenibacillus sp. B. cereus |
28 — — |
2 4 —- |
29 — 1 |
PEN–CIP PEN–AZM CIP–AZM |
9 1 1 |
S. aureus
S. epidermidis S. epidermidis S. epidermidis |
5 4 1 1 |
— — — — |
— — — — |
| PEN–CFO–EST PEN–CFO–AZM |
10 1 |
B. cereus
Paenibacillus sp. B. cereus |
— — — |
— 2 — |
8 — 1 |
CFO–CIP–AZM | 6 |
S. epidermidis
S. saprophyticus |
5 1 |
— — |
— — |
| PEN–CFO–CIP–AZM | 54 |
S. epidermidis
S. capitis S. saprophyticus S. aureus |
35 17 1 1 |
— — — — |
— — — — |
||||||
| Susceptible to all ATM | 92 |
Bacillus sp. B. subtilis B. vallismortis B. pumilus B. licheniformis B. cereus |
49 25 4 2 1 1 |
2 — — — — — |
4 4 — — — — |
Susceptible to all ATM | 19 |
S. haemolyticus
S. lugdunensis |
4 15 |
— — |
— — |
1ST, isolates obtained from skin samples previously submitted to the first cycle of treatment with penicillin and streptomycin in the skin bank; 2ND, isolates obtained from skin samples previously submitted to the second cycle of treatment with vancomycin; ATM, antimicrobials; AZM, azithromycin; CFO, cefoxitin; CIP, ciprofloxacin; CNS, coagulase-negative staphylococci; EST, streptomycin; PEN, penicillin; WT, without treatment